Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Inclusion Criteria:

1. Histologically proven primary thoracic esophageal squamous cell carcinoma

2. According to the esophageal AJCC2009 7th to determine new stage IV esophageal cancer

3. The subject has PD after first-line chemotherapy or radiation within a year

4. Presence of at least one index lesion measurable by CT scan or MRI according to RECIST 1.1

5. Can eat more than liquid diet; No signs before esophageal perforation

6. 18~75 years

7. PS:0-1

8. Life expectancy of ≥ 3 months

9. ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L

10. TB ≤ UNL； ALT/AST ≤ 2.5×UNL，AKP ≤ 5×UNL

11. Ccr≤ UNL,Scr≥60 mL/min

12. Normal electrocardiogram (ecg), the body had no unheal wounds

13. Radiotherapy before within the scope of the normal dose and not affect subsequenttreatment

14. Prior to biological agents, especially e. coli genetically engineered products withoutsevere allergic reactions

15. Signed written informed consent

Exclusion Criteria:

1. Breast-feeding or pregnant women, no effective contraception if risk of conceptionexists

2. Chronic diarrhea, enteritis, intestine obstruction which are not under control

3. Esophageal obstruction cannot eat liquid completely, esophagus have deep ulcerperforation or hematemesis; Esophageal cancer common complications such as anastomoticleakage, serious lung complications, etc.

4. A second primary tumor (except skin basal cell carcinoma)

5. The original serious heart disease, including: higher risk of congestive heartfailure, unable to control arrhythmia, unstable angina, myocardial infarction, severevalvular heart disease, and resistant hypertension

6. With uncontrol nerve, mental illness or mental disorders, compliance is poor, can'tcooperate with accounts and response to treatment; Primary brain tumors or CNSmetastases illness did not get a control, has obvious cranial hypertension or nervemental symptoms

7. With bleeding tendency

8. Has inherited bleeding evidence of physical or blood coagulation disorder

9. With clear chemotherapy drug allergy

10. Other researchers believe that patients should not participate in this testing